Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,000 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Edwards Lifesciences Trading Up 1.7 %

NYSE EW opened at $68.25 on Thursday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a 50-day simple moving average of $73.32 and a 200 day simple moving average of $83.72. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $41.11 billion, a PE ratio of 29.42, a P/E/G ratio of 2.79 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the prior year, the business posted $0.66 EPS. Edwards Lifesciences’s revenue was up 6.7% on a year-over-year basis. Research analysts forecast that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently bought and sold shares of the company. DSM Capital Partners LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth $28,000. Crewe Advisors LLC bought a new stake in shares of Edwards Lifesciences in the first quarter worth about $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences during the second quarter worth about $29,000. Riverview Trust Co bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $34,000. Finally, Pingora Partners LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $38,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Daiwa America upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, July 31st. Royal Bank of Canada cut their price target on Edwards Lifesciences from $101.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, July 25th. Baird R W lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Finally, Truist Financial cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $110.00 to $82.00 in a research report on Thursday, July 25th. Fifteen analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $80.81.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.